American Association for Cancer Research Annual Meeting (AACR)

Previous studies found calcium channel blockers could prevent pancreatic cancer, but have neglected to consider the effects of short-acting CCBs.

At AACR 2018, Dr. Alexander Eggermont presented results of KEYNOTE-045/EORTC 1325-MG, in which melanoma patients with recurrence on placebo can receive pembrolizumab.

Dr. Stephen Baylin discusses his 2018 AACR meeting presentation on SU2C research into using epigenetic therapy to boost immune checkpoint therapy.

Dr. Elizabeth Plimack discusses her 2018 AACR meeting presentation on recent advances in systemic therapy for bladder cancer.

Mateusz Opyrchal, MD, PhD, talks about how the Inhibition of AURKA induces Raf1-independent activation of MAPK pathway in breast cancer cells.

Dual HER2 blockade with trastuzumab and lapatinib yielded good response rates in HER2-amplified, RAS wild type, treatment-refractory metastatic colorectal cancer patients, according to results of the HERACLES study.

This video examines current research on the use of vaccines in low-grade glioma for the prevention of high-grade disease.

In this video, Michael Ciesielski, PhD, of Roswell Park Cancer Institute in Buffalo, talks about circulating exosomes isolated from the serum of malignant glioma patients enrolled in a completed phase I clinical trial of an anti-survivin vaccine (SurVaxM).

This video examines a study that used liquid biopsies to monitor disease progression in patients with bladder cancer.

In this video, David Goodrich, PhD, of Roswell Park Cancer Institute in Buffalo, discusses treatment resistance and disease relapse in prostate cancer.

A nivolumab/ipilimumab combination significantly improved overall survival for advanced melanoma patients.

This video reviews the latest trials and research on immunotherapeutic agents being tested in breast cancer.

This video highlights a novel scoring system using microRNA signatures that predicted poor overall survival and bone metastasis in patients with luminal A breast cancer.

Unmutated immunoglobulin heavy chain variable region gene (IGHV) status does not adversely impact survival among ibrutinib-treated patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

This video examines how a specific combination of KIR/KIR-ligand genotypes in high-risk neuroblastoma patients may be predictive of outcomes when adding dinutuximab to isotretinoin.

This video reviews results of the ZUMA-1 trial, which tested the CAR T-cell therapy axicabtagene ciloleucel in patients with advanced non-Hodgkin lymphoma.

In this interview we discuss long-term data on the anti–PD-L1 immunotherapy atezolizumab in metastatic triple-negative breast cancer.

We spoke with Dr. Gerald Falchook about the first human study of a first-in-class molecule, fatty acid synthase inhibitor known as TVB-2640 for advanced solid tumors.

This video examines results of a study that found that shorter sleep duration was linked with an increased risk of death among patients with prostate cancer.

An analysis from Project Genomics Evidence Neoplasia Information Exchange (GENIE) was presented at the American Association for Cancer Research Annual Meeting.

This video examines phase II results of a single-arm trial that tested checkpoint inhibition plus the IDO–pathway inhibitor indoximod in patients with melanoma.

This video reviews results of the phase II CHRONOS-1 trial, a single-arm study evaluating the investigational agent copanlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

In this interview we discuss the use of CTCs and circulating tumor DNA for prognosis and disease monitoring in patients with breast cancer.

This video highlights preclinical activity of a novel FGFR inhibitor that has been tested alone and in combination with antihormonal therapy in breast cancer cell lines.

An experimental compound known as G100 may be a potentially viable agent for local control of metastatic soft tissue sarcomas.

The combination of an intratumoral injection of CVA21 and ipilimumab has demonstrated durable response with minimal toxicity in patients with advanced melanoma.

We spoke with Dr. Julie Brahmer about how survival rates are starting to improve with the use of nivolumab in non-small cell lung cancer.

In this interview, we speak with Dr. Robert Ferris about the results from the CheckMate-141 study, which investigated the efficacy of nivolumab in head and neck cancer.

Patients with metastatic Merkel cell carcinoma treated with pembrolizumab (Keytruda, Merck) as a first-line therapy had durable responses in a phase II clinical trial.

Results of the I-SPY 2 TRIAL found that the neoadjuvant combination of T-DM1 plus pertuzumab resulted in a greater benefit to HER2-positive breast cancer patients compared with paclitaxel plus trastuzumab.